{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 27,
  "pageCount": 32,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/27",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.02,
        "y": 0.32
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6e02e33-2fb3-4b5a-bae9-1cd224e1a582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.02,
        "y": 0.68
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d9ff975-5980-4629-80d2-4e2488ca2972",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.09,
        "y": 0.67
      },
      "kind": "list",
      "text": "Pipeline of Novel Mechanisms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1aab95db-1ac2-445b-b524-0760e6b2a39f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.09,
        "y": 0.3
      },
      "kind": "list",
      "text": "Company Built at Scale with Differentiated Approach",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "644079fc-0621-4508-ae3c-a536faacb91c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.25,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and commercial potential creating rich set of catalysts\nLead program, navacaprant (KOR antagonist) demonstrated positive Phase 2 clinical data and is currently in Phase 3 trials with topline data expected in 2H 2024\nMid-stage clinical program, NMRA-511 (V1aR antagonist) expected to enter AD agitation studies in 1H 2024\nIND submission planned for NMRA-266 (M4 PAM) in the fourth quarter of 2023\nDeep preclinical pipeline with near-IND assets focused on Parkinson's, ALS and other indications",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be4c0f73-d0d1-4b85-a395-622fd424dcc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.25,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Raised >$600M to date from leading investors and collaborators, including Series B close in Oct. 2022\nLed by experienced company builders and leading neuroscience drug developers\nPrecision approach leveraging unique data sciences capability underlying development strategy\nStrong capital position to support growth with compelling use of proceeds story for proposed offering\nStrategy supported by long-dated composition of matter patents for each of our programs, into 2041+",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f31e762a-681d-4e94-aae2-3bb38c3d7cff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Building a Company with the Scale and Scope to Address the Brain Disease Crisis for Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1727d59a-25d4-48f8-923f-adf3714e8606",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0aec0133-6ed1-4f0b-9bd4-54c778a3d3aa",
      "evidence": "Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and commercial potential creating rich set of catalysts",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}